Literature DB >> 16817756

Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease.

Patricia E Tam1.   

Abstract

Coxsackievirus (CVB) infection is a significant cause of myocarditis and dilated cardiomyopathy (DCM). Heart disease may be caused by direct cytopathic effects of the virus, a pathologic immune response to persistent virus, or autoimmunity triggered by the viral infection. CVB interacts with its host at multiple stages during disease development. Signaling through viral receptors may alter the intracellular environment in addition to facilitating virus entry. Viral genetic determinants that encode cardiovirulence have been mapped and may change depending on the nutritional status of the host. Virus persistence is directly associated with pathology, and recent work demonstrates that CVB evolves into a slowly replicating form capable of establishing a low-grade infection in the heart. The innate immune response to CVB has taken on increasing importance because of its role in shaping the development of the adaptive immune response that is responsible for cardiac pathology. Studies of T cell responsiveness and the development of autoimmunity at the molecular level are beginning to clarify the mechanisms through which CVB infection causes inflammatory heart disease.

Entities:  

Mesh:

Year:  2006        PMID: 16817756     DOI: 10.1089/vim.2006.19.133

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  53 in total

Review 1.  Macrophage diversity in cardiac inflammation: a review.

Authors:  Jobert G Barin; Noel R Rose; Daniela Ciháková
Journal:  Immunobiology       Date:  2011-06-30       Impact factor: 3.144

2.  The immunity-related GTPase Irgm3 relieves endoplasmic reticulum stress response during coxsackievirus B3 infection via a PI3K/Akt dependent pathway.

Authors:  Zhen Liu; Huifang M Zhang; Ji Yuan; Xin Ye; Gregory A Taylor; Decheng Yang
Journal:  Cell Microbiol       Date:  2011-11-10       Impact factor: 3.715

Review 3.  The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease.

Authors:  Udi Nussinovitch; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

4.  Neutralizing activity induced by the attenuated coxsackievirus B3 Sabin3-like strain against CVB3 infection.

Authors:  Nadia Jrad-Battikh; Amira Souii; Leila Oueslati; Mahjoub Aouni; Didier Hober; Jawhar Gharbi; Manel Ben M'hadheb-Gharbi
Journal:  Curr Microbiol       Date:  2013-12-10       Impact factor: 2.188

5.  Focal adhesion kinase mediates the interferon-gamma-inducible GTPase-induced phosphatidylinositol 3-kinase/Akt survival pathway and further initiates a positive feedback loop of NF-kappaB activation.

Authors:  Zhen Liu; Huifang M Zhang; Ji Yuan; Travis Lim; Alhousseynou Sall; Gregory A Taylor; Decheng Yang
Journal:  Cell Microbiol       Date:  2008-04-28       Impact factor: 3.715

6.  MOPS and coxsackievirus B3 stability.

Authors:  Steven D Carson; Susan Hafenstein; Hyunwook Lee
Journal:  Virology       Date:  2016-12-08       Impact factor: 3.616

7.  Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Th1 immune responses.

Authors:  Yan Yue; Jun Gui; Wenqing Ai; Wei Xu; Sidong Xiong
Journal:  PLoS One       Date:  2011-03-22       Impact factor: 3.240

Review 8.  Myocarditis.

Authors:  Leslie T Cooper
Journal:  N Engl J Med       Date:  2009-04-09       Impact factor: 91.245

9.  Myocarditis mimicking acute coronary syndrome following influenza B virus infection: a case report.

Authors:  Jun Muneuchi; Yoshiaki Kanaya; Tomoko Takimoto; Takayuki Hoshina; Koichi Kusuhara; Toshiro Hara
Journal:  Cases J       Date:  2009-06-25

10.  Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway.

Authors:  Christopher C Kemball; Stephanie Harkins; Jason K Whitmire; Claudia T Flynn; Ralph Feuer; J Lindsay Whitton
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.